These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 26763834)

  • 1. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study.
    Sun W; Cui H; Li N; Wei Y; Lai S; Yang Y; Yin X; Chen DF
    Hepatol Res; 2016 Aug; 46(9):862-70. PubMed ID: 26763834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Validation Study of Non-invasive Scoring Systems for Assessing Severity of Hepatic Fibrosis in a Cohort of South Indian Patients With Non-alcoholic Fatty Liver Disease.
    Mathew JF; Panackel C; Jacob M; Ramesh G; John N
    J Clin Exp Hepatol; 2024; 14(5):101407. PubMed ID: 38699513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease.
    Xu HW; Hsu YC; Chang CH; Wei KL; Lin CL
    Hepatol Int; 2016 Mar; 10(2):340-6. PubMed ID: 26676626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.
    Xiao G; Zhu S; Xiao X; Yan L; Yang J; Wu G
    Hepatology; 2017 Nov; 66(5):1486-1501. PubMed ID: 28586172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.
    Zhou YJ; Ye FZ; Li YY; Pan XY; Chen YX; Wu XX; Xiong JJ; Liu WY; Xu SH; Chen YP; Zheng MH
    United European Gastroenterol J; 2019 Oct; 7(8):1124-1134. PubMed ID: 31662869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD.
    Demir M; Lang S; Schlattjan M; Drebber U; Wedemeyer I; Nierhoff D; Kaul I; Sowa J; Canbay A; Töx U; Steffen HM
    PLoS One; 2013; 8(3):e58360. PubMed ID: 23555578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
    World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease.
    Demir M; Lang S; Nierhoff D; Drebber U; Hardt A; Wedemeyer I; Schulte S; Quasdorff M; Goeser T; Töx U; Steffen HM
    J Clin Gastroenterol; 2013 Sep; 47(8):719-26. PubMed ID: 23442837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
    Younes R; Caviglia GP; Govaere O; Rosso C; Armandi A; Sanavia T; Pennisi G; Liguori A; Francione P; Gallego-Durán R; Ampuero J; Garcia Blanco MJ; Aller R; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; Pareja MJ; Zaki MYW; Grieco A; Fracanzani AL; Valenti L; Miele L; Fariselli P; Petta S; Romero-Gomez M; Anstee QM; Bugianesi E
    J Hepatol; 2021 Oct; 75(4):786-794. PubMed ID: 34090928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience.
    Rath MM; Panigrahi MK; Pattnaik K; Bhuyan P; Kar SK; Misra B; Misra D; Meher C; Agrawal O; Rath J; Singh SP
    J Clin Exp Hepatol; 2016 Dec; 6(4):291-296. PubMed ID: 28003718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
    Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels.
    Yoneda M; Imajo K; Eguchi Y; Fujii H; Sumida Y; Hyogo H; Ono M; Suzuki Y; Kawaguchi T; Aoki N; Sata M; Kanemasa K; Kohgo Y; Saibara T; Chayama K; Itoh Y; Yoshikawa T; Anzai K; Fujimoto K; Okanoue T; Nakajima A;
    J Gastroenterol; 2013 Sep; 48(9):1051-60. PubMed ID: 23184095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of simple scoring systems for a public health approach in the management of non-alcoholic fatty liver disease patients.
    Zain SM; Tan HL; Mohamed Z; Chan WK; Mahadeva S; Basu RC; Mohamed R
    JGH Open; 2020 Dec; 4(6):1155-1161. PubMed ID: 33319051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Liver Fibrosis Using Non-invasive Screening Tools in Individuals With Diabetes Mellitus and Metabolic Syndrome.
    Shaji N; Singhai A; Sarawagi R; Pakhare AP; Mishra VN; Joshi R
    Cureus; 2022 Feb; 14(2):e22682. PubMed ID: 35386158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.